International Clinical Trial: A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Trastuzumab and Pertuzumab Combined with an Aromatase Inhibitor and Dalpiciclib in Patients with HR+/HER2+ Early Breast Cancer

Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126436) titled 'A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Trastuzumab and Pertuzumab Combined with an Aromatase Inhibitor and Dalpiciclib in Patients with HR+/HER2+ Early Breast Cancer' on June 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Guangdong Provincial Hospital of Chines Medicine

Condition: Breast Cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-06-30

Target Sample Size: test group:48;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=324928

Published by HT ...